In re Application of:

Andrea Crisanti.

PATENT

Attorney Docket No.: TROJAN1100-1

Application No.: 10/789,403 Filed: February 27, 2004

Page 2

Amendments to the Claims

Please amend claims 1, 6, and 15 as provided below.

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

- 1. (Currently Amended) A conjugate comprising:
 - (a) a first region comprising the homeodomain of antennapedia; and
 - (b) a second region at the C-terminus of the first region and not naturally associated with the first region;

wherein the second region comprises a protein of at least 100 amino acids, and wherein at least the first region is non-denatured.

- 2. (Withdrawn) The conjugate according to claim 1, wherein the first and second regions are associated via a disulfide bond.
- 3. (Withdrawn) The conjugate according to claim 2, wherein the second region comprises an NOI.
- 4. (Original) The conjugate according to claim 1, in the form of a fusion protein.
- 5. (Canceled)
- 6. (Currently Amended) The conjugate according to claim [[5]] 1, wherein the second region is a functional or regulatory protein.
- 7. (Withdrawn) The conjugate according to claim 5, wherein the second region is an antigen.
- 8. (Withdrawn) The conjugate according to claim 5, wherein the second region is a DNA binding domain.

In re Application of:

Andrea Crisanti.

Application No.: 10/789,403 Filed: February 27, 2004

Page 3

9. (Withdrawn) The conjugate according to claim 8, wherein the second region further comprises an NOI.

PATENT

Attorney Docket No.: TROJAN1100-1

- 10. (Withdrawn) The conjugate according to claim 8, wherein the second region is a histone protein.
- 11. (Withdrawn) The conjugate according to claim 1, wherein the second region comprises an NOI.
- 12. (Withdrawn) The conjugate according to claim 1, for use in an expression system.
- 13. (Original) A pharmaceutical composition comprising the conjugate of claim 1, in combination with a pharmaceutically-acceptable carrier.
- 14. (Original) The pharmaceutical composition according to claim 13, in the form of a vaccine.
- 15. (Currently Amended) A conjugate prepared by a method comprising the steps:
 - (i) culturing a host cell transformed with an expression vector comprising a nucleic acid encoding a conjugate according to claim [[1]] 4 under conditions which provide for the expression of the conjugate within the host cell; and
 - (ii) recovering the conjugate by affinity purification under non-denaturing conditions.
- 16. (Original) The conjugate prepared according to claim 15, wherein the conjugate comprises an amino acid tail that binds to an immobilised substrate.